GlassScriptPhysician profile
Bethany D Leighton
NPI 1326169087
$1,656.39
in general payments reported to CMS, 2019-2025
17 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $446 · 2021: $494 · 2022: $286 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $542.69 | 2019-2025 | |
| Abbvie INC. | $371.20 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $148.59 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $103.60 | 2021 | |
| Lilly USA, LLC | $95.67 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $70.81 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $67.14 | 2019-2020 | |
| Novo Nordisk INC | $52.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.36 | 2021 | |
| Allergan, INC. | $30.56 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.60 | 2022 | |
| Phadia US INC. | $17.87 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.83 | 2019 | |
| Shire North American Group INC | $15.63 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $14.02 | 2020 | |
| Glaxosmithkline, LLC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Leighton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.